Market Place
Sourcing Support
Shuttle Pharma to Participate in Lytham Partners Investor Summit
07 Jan 2025 //
GLOBENEWSWIRE
Shuttle Pharma Partners with UCSF to Advance PSMA Program
19 Dec 2024 //
GLOBENEWSWIRE
Shuttle Pharma Expands Patient Enrollment for Glioblastoma Trial
26 Nov 2024 //
GLOBENEWSWIRE
Shuttle Pharma Q3 2024 Corporate Update
13 Nov 2024 //
GLOBENEWSWIRE
Shuttle Pharma Doses First Patients in Glioblastoma Trial
29 Oct 2024 //
GLOBENEWSWIRE
Shuttle Pharma Pays Off Senior Secured Convertible Note
29 Oct 2024 //
GLOBENEWSWIRE
Shuttle Pharma Prices $4.5M Public Offering Under Nasdaq Rules
29 Oct 2024 //
GLOBENEWSWIRE
Shuttle Pharmaceuticals to Present at ThinkEquity Conference
28 Oct 2024 //
#N/A
Shuttle Pharma Completes Phase 2 Trial Enrollment for Glioblastoma
28 Oct 2024 //
#N/A
Shuttle Pharma Expands Trial For Glioblastoma Treatment
16 Sep 2024 //
GLOBENEWSWIRE
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
04 Sep 2024 //
GLOBENEWSWIRE
Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
28 Aug 2024 //
GLOBENEWSWIRE
Shuttle Pharma Receives Nasdaq Non-Compliance Notice For Listing Rule
26 Aug 2024 //
GLOBENEWSWIRE
Shuttle Pharma Ready To Enroll Patients In Phase 2 Glioblastoma Trial
14 Aug 2024 //
GLOBENEWSWIRE
Shuttle Pharma`s HDAC Inhibitor Shows Promise For ER+ Breast Cancer
19 Jul 2024 //
GLOBENEWSWIRE
Shuttle Pharma Appoints Timothy Lorber As CFO
18 Jun 2024 //
GLOBENEWSWIRE
Shuttle Pharma To Participate At Lytham Spring Conference
22 May 2024 //
GLOBENEWSWIRE
Shuttle Pharma Provides First Quarter 2024 Corporate Update
14 May 2024 //
GLOBENEWSWIRE
Shuttle Pharma At Planet MicroCap May 1-2
23 Apr 2024 //
GLOBENEWSWIRE
Shuttle Pharma to Present at the Emerging Growth Conference on April 4, 2024
03 Apr 2024 //
GLOBENEWSWIRE
Shuttle Pharma to Present at the Emerging Growth Conference on March 6, 2024
05 Mar 2024 //
GLOBENEWSWIRE
Shuttle Receives FDA Approval to Proceed with Phase II Trial of Ropidoxuridine
08 Jan 2024 //
PR NEWSWIRE
Shuttle Pharma Submits IND Application to the U.S. FDA for Ropidoxuridin
11 Dec 2023 //
PR NEWSWIRE
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update
14 Nov 2023 //
PR NEWSWIRE
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program
31 Oct 2023 //
PR NEWSWIRE
Shuttle Pharma to Participate in Lytham Partners Fall 2023 Investor Conference
10 Oct 2023 //
PR NEWSWIRE
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine
25 Sep 2023 //
PR NEWSWIRE
Shuttle Pharma Participates in Hampton University Health Fair
13 Sep 2023 //
PR NEWSWIRE
Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform
11 Sep 2023 //
PR NEWSWIRE
Shuttle Pharma`s HDAC6 Inhibitor Shown to Stimulate Innate Imm. Response
29 Aug 2023 //
PR NEWSWIRE
Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update
15 Aug 2023 //
PR NEWSWIRE
Shuttle Pharmaceuticals Completes Manufacturing of API for Use in Trial
03 Aug 2023 //
PR NEWSWIRE
Shuttle to Participate in the Lytham Partners Spring 2023 Investor Conference
17 May 2023 //
PR NEWSWIRE
Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University
22 Mar 2023 //
PR NEWSWIRE
Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update
15 Mar 2023 //
PR NEWSWIRE
Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Ropidoxuridine
09 Mar 2023 //
PR NEWSWIRE
Shuttle Pharma, UI Pharma Partner to Manufacture Ropidoxuridine
09 Mar 2023 //
CONTRACT PHARMA
Shuttle Pharma Expands Laboratory Space to Advance Drug Development Pipeline
23 Feb 2023 //
PR NEWSWIRE
Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18
17 Jan 2023 //
PR NEWSWIRE
Shuttle Announces Private Placement of $4.3M of Secured Convertible Note
12 Jan 2023 //
PR NEWSWIRE
Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications
10 Jan 2023 //
PR NEWSWIRE
Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications
06 Dec 2022 //
PRNEWSWIRE
Shuttle Pharmaceuticals Provides Third Quarter 2022 Corporate Update
15 Nov 2022 //
PRNEWSWIRE
Shuttle engages CRO Theradex for brain tumour treatment trial
04 Nov 2022 //
CLINICALTRIALSARENA
Shuttle Pharma Engages Theradex Oncology in Preparation for Clinical Study
03 Nov 2022 //
PRNEWSWIRE
Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors
01 Nov 2022 //
BARRONS
Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine
20 Sep 2022 //
PRNEWSWIRE
Shuttle Pharmaceuticals Awarded New HDAC Inhibitor Patents for Cancer Treatment
15 Sep 2022 //
PRNEWSWIRE
Why Shares of Shuttle Pharmaceuticals Jumped 160.4% This Week
09 Sep 2022 //
FOOL
Shuttle Pharmaceuticals Announces Closing of Initial Public Offering
06 Sep 2022 //
PRNEWSWIRE
Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol "SHPH"
31 Aug 2022 //
PRNEWSWIRE
Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering
30 Aug 2022 //
PRNEWSWIRE
Shuttle Pharma Awarded New Patent for Selective Inhibitors for Cancer Treatment
29 Jul 2021 //
PRNEWSWIRE
